AbbVie Inc. (NYSE: ABBV) shares advanced 1.72% to $295.79, a gain of $4.99, after the pharmaceutical company reported third-quarter revenue growth of 10.3% and adjusted earnings that more than doubled year over year. Alongside the results, the company raised its full-year 2026 earnings guidance and announced a dividend increase.

Third-quarter revenue totaled $17.404 billion, up 10.3% from the previous year, while operational revenue increased 10.5%, reflecting stronger demand across AbbVie's major pharmaceutical businesses. Adjusted diluted earnings per share reached $3.82, and GAAP diluted EPS stood at $2.37.

The quarter highlighted continued growth in immunology and neuroscience alongside weaker performance in aesthetics. AbbVie also completed its acquisition of Apogee Therapeutics to strengthen its immunology development pipeline, increased its 2026 earnings outlook, and announced higher shareholder distributions.

Immunology and Neuroscience Drive Growth

AbbVie's immunology portfolio generated $9.165 billion in third-quarter revenue, an increase of 16.3% year over year. Skyrizi contributed $5.776 billion, up 22.7% on a reported basis, while Rinvoq generated $2.706 billion, marking a 23.9% gain for the quarter. Combined, the two drugs brought in $8.482 billion, roughly 92% of the portfolio's quarterly total.

Humira revenue fell 31.2% to $683 million as competition continued to affect its sales. The combined performance of Skyrizi and Rinvoq carried overall immunology growth and underscored the portfolio's shifting composition as Humira's sales decline.

The neuroscience division posted $3.389 billion in revenue, up 19.4% annually. Vraylar sales rose 14.3% to $1.068 billion, and Botox Therapeutic reached $1.080 billion, each crossing the $1 billion mark for the quarter. Ubrelvy generated $449 million, while Qulipta contributed $398 million and recorded 38.2% reported growth, making it one of the portfolio's strongest performers. Vyalev added $286 million as AbbVie continued to expand its neuroscience business. The results demonstrated broad growth across several treatments in the division.

Oncology and Aesthetics Deliver Mixed Results

AbbVie's oncology portfolio generated $1.696 billion in third-quarter revenue, up 0.8% year over year. Venclexta revenue rose 10.7% to $803 million and Elahere increased 31% to $224 million, but Imbruvica declined 26.1% to $522 million, limiting the division's overall growth.

The aesthetics portfolio recorded $1.176 billion in revenue, a 1.4% annual decline. Botox Cosmetic generated $669 million, up 4.9% from the previous year, while Juvederm revenue fell 11.9% to $222 million during the quarter.

On profitability, AbbVie reported a GAAP gross margin of 75.4% and an adjusted gross margin of 85.1%. Selling, general and administrative expenses represented 23.5% of revenue on a GAAP basis, and the adjusted operating margin reached 48.7%, compared with 36% under GAAP accounting.

Guidance Raised and Dividend Increased

Following its third-quarter performance, AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a range of $13.95–$13.99 per share, up from the prior forecast of $13.76–$13.96, lifting the midpoint of the range by $0.11 to $13.97. The updated range includes a $0.69 per-share impact from acquired research and development expenses and milestones.

The company completed its acquisition of Apogee Therapeutics during the quarter. The transaction strengthens AbbVie's immunology pipeline, expands its potential treatment development opportunities, and forms part of a broader strategy to support future pharmaceutical growth.

AbbVie also announced a 5.2% increase in its 2027 dividend, with the higher payments beginning with the distribution scheduled for February 2027. The move extends the company's shareholder distribution strategy alongside its improving financial performance.

The latest results reflect continued revenue expansion across AbbVie's major pharmaceutical businesses, with stronger immunology and neuroscience sales offsetting declines in selected oncology and aesthetics products. The raised earnings guidance and dividend growth provide further detail on the company's financial outlook. The pace of the portfolio's shift from Humira toward Skyrizi and Rinvoq, together with the integration of Apogee's immunology programs, provides concrete markers to track as AbbVie works toward its updated 2026 targets.

Source: Blockonomi